- AN IMPROVED PROCESS FOR THE SEPARATION OF ENANTIOMERICALLY PURE COMPOUNDS
-
The present patent application relates to an improved process for the separation of enantiomerically pure compounds. Specifically it relates to separation of enantiomerically pure Rivastigmine, Duloxetine, Escitalopram and their intermediates in high yields.
- -
-
Page/Page column 16; 17
(2009/12/28)
-
- Amorphous and crystalline forms of rivastigmine hydrogentartrate
-
Rivastigmine hydrogentartrate in amorphous form or in a crystalline form characterized by an X-ray powder diffraction pattern exhibiting peaks at 2Θ values of 5.1, 14.7, 16.5, 17.6, 18.6, 20.4, 21.1° ± 0.2° (Form I), or 2Θ values of 9.5, 11.3, 13.2, 14.1, 15.5, 19.1 20.0° ± 0.2° (Form II), methods for its preparation and pharmaceutical compositions comprising the same.
- -
-
Page/Page column 11
(2008/12/06)
-
- AN EFFICIENT METHOD FOR PREPARATION OF (S)-3-[(1-DIMETHYL AMINO)ETHYL]-PHENYL-N-ETHYL-N-METHYL-CARBAMATE
-
The present invention relates to a method for preparation of substituted phenyl carbamate and pharmaceutically acceptable salts thereof, which are of current pharmaceutical interest. The substituted phenyl carbamate and pharmaceutically acceptable salts thereof are useful to raise cholinergic activity in the central nervous system and useful in treatment of diseases such as Alzheimer's disease, Down's syndrome, Huntingdon's chorea, Friedrich's ataxia etc. (S)-3-[(1-dimethyl amino)ethyl]- phenyl-N-ethyl-N-methyl-carbamate (I) is the active ingredient of the pharmaceutical composition referred in US 5,602,176. This compound is also used to induce selective inhibition of acetylcholinesterase activity in the brain.
- -
-
Page/Page column 4; 11
(2010/11/30)
-